Affiliate plans sale of 4,991 RMD shares via Fidelity (NYSE: RMD)
An affiliate, Michael Farrell, has filed a Form 144 indicating a proposed sale of 4,991 shares of ResMed Inc. (NYSE: RMD) common stock on April 7, 2026, through Fidelity Brokerage Services LLC. This filing also discloses three prior sales of the same share amount on January 7, February 9, and March 9, 2026, with respective dollar proceeds. The consistent monthly dispositions suggest a steady liquidation pattern rather than a single large block sale.
Robinhood Asset Management Boosts ResMed Stake
Robinhood Asset Management LLC has acquired a new stake of 2,622 shares in ResMed Inc. (NYSE:RMD), a medical equipment provider specializing in sleep apnea and respiratory care devices. This investment, valued at approximately $632,000, signals Robinhood's confidence in ResMed's growth potential and market position within an industry experiencing increased demand for sleep disorder treatments. The hedge fund focuses on emerging growth opportunities, and ResMed's strong sales of CPAP machines contribute to its appeal.
ResMed Officer Sandercock Discloses Ongoing Insider Share Sales Under Rule 144
ResMed officer Brett Sandercock plans to sell 1,000 shares of vested restricted stock valued at approximately $224,310 under Rule 144. These sales, executed through a Rule 10b5-1 plan adopted in February 2025, are described as routine insider disposals for portfolio diversification rather than an indication of adverse company fundamentals. Sandercock has also sold 3,000 shares in the past three months via pre-arranged transactions.
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144
ResMed director Peter C. Farrell is set to sell 2,000 shares of the company's common stock on April 1, 2026, under a prearranged Rule 10b5-1 trading plan. This sale is part of a continuing pattern of insider disposals, which Farrell states is for portfolio diversification and does not indicate any undisclosed negative information about ResMed's operations. The stock currently holds a Buy rating from analysts with a price target of A$36.00.
Boston Scientific closes buyout of Valencia Technologies
Boston Scientific has finalized its acquisition of Valencia Technologies, a move that significantly strengthens its position in the competitive urge urinary incontinence market. The buyout gives Boston Scientific control of eCoin, a tibial nerve stimulator that will compete directly with Medtronic’s Altaviva. Analysts believe this market is largely under-penetrated, offering substantial growth opportunities for Boston Scientific as it leverages its existing urology commercial capabilities.
4,837 Shares in ResMed Inc. $RMD Acquired by Runnymede Capital Advisors Inc.
Runnymede Capital Advisors Inc. has acquired a new stake of 4,837 shares in ResMed Inc. (NYSE:RMD) during Q4, valued at approximately $1.165 million. This comes as institutional ownership in ResMed stands at about 54.98%, with various other firms adjusting their positions. While analysts maintain a "Moderate Buy" rating for ResMed with a consensus target price of $299.27, insider selling has occurred, with director Peter C. Farrell and CEO Michael J. Farrell selling shares recently.
Biotech layoff pick back up as 14 companies cut 745 jobs in Q1
In the first quarter of 2026, 14 biotech companies announced layoffs, resulting in 745 job cuts. This number marks an increase from the previous quarter, which saw 476 workers lose their jobs. Companies such as Tessera, Vertex, and Takeda were among those implementing cuts.
Wealth Enhancement Advisory Services LLC Has $1.66 Million Stock Holdings in ResMed Inc. $RMD
Wealth Enhancement Advisory Services LLC significantly reduced its stake in ResMed Inc. by 81.9% in Q4, ending with $1.66 million in holdings. Meanwhile, other large institutions like Nordea Investment Management, Landscape Capital Management, and Allianz Asset Management increased their positions in the medical equipment provider. ResMed (NYSE: RMD) posted strong earnings, exceeding analyst expectations with EPS of $2.81 versus $2.68 and revenue up 11% to $1.42 billion, maintains a "Moderate Buy" rating, and declared a quarterly dividend of $0.60 per share which represents a $2.40 annualized dividend and a dividend yield of 1.1%.
Element Squared LLC Buys Shares of 6,067 ResMed Inc. $RMD
Element Squared LLC initiated a new position in ResMed Inc. (NYSE:RMD) during Q4, acquiring 6,067 shares valued at approximately $1.46 million. This investment comes as ResMed reported strong quarterly earnings, beating consensus estimates with an EPS of $2.81 and an 11% year-over-year revenue increase to $1.42 billion. Despite recent insider share sales, analysts maintain a "Moderate Buy" rating for ResMed, with an average price target of $299.27.
Aberdeen Group Reduces Stake in ResMed Inc.
Aberdeen Group plc, a major institutional investor, has reduced its stake in ResMed Inc. (NYSE: RMD) by 13.6% in the fourth quarter, selling 37,737 shares. This move leaves them with 239,236 shares valued at approximately $57.6 million, and could signal concerns about the medical equipment provider's future outlook or valuation, potentially influencing other investors. The sale follows a period of strong performance for ResMed's stock, which has since seen a pullback.
Aberdeen Group plc Sells 37,737 Shares of ResMed Inc. $RMD
Aberdeen Group plc reduced its stake in ResMed Inc. by 13.6% in Q4 2025, selling 37,737 shares and retaining 239,236 shares valued at $57.63 million. Despite insider selling, including CEO Michael J. Farrell's sale of shares, ResMed exceeded quarterly expectations with $2.81 EPS and $1.42 billion in revenue. The company maintains a "Moderate Buy" consensus rating with an average price target near $299 and pays a quarterly dividend of $0.60, yielding approximately 1.1%.
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Analysts
ResMed Inc. (NYSE:RMD) has received an average "Moderate Buy" rating from fourteen analysts, with a consensus twelve-month price target of $299.27. Recent analyst reports show a mix of "overweight," "buy," and "hold" ratings, with some price target adjustments. Insider selling by CEO Michael J. Farrell and Director Peter C. Farrell was noted, while institutional investors like Landscape Capital Management and Nordea Investment Management increased their stakes in the company.
Insider Sell: Brett Sandercock Sells Shares of ResMed Inc (RMD)
ResMed Inc's CFO subsidiary, Brett Sandercock, sold 1,000 shares of RMD on April 1, 2026, reducing his holdings to 83,495 shares. Over the past year, Sandercock has sold 26,527 shares with no buys, contributing to a total of 44 insider sells for the company. ResMed Inc, trading at $224.31, is considered modestly undervalued with a price-to-GF-Value ratio of 0.83.
RESMED INC. R (RME.MU) Q1 FY2025 earnings call transcript
ResMed (RME.MU) reported strong financial results for Q1 FY2025, with revenue reaching $1.22 billion, an 11% year-over-year increase, and EPS growth of 34%. The company also achieved a significant gross margin expansion to 59.2%, reaffirming its full-year guidance of 59%-60%. This positive performance is supported by momentum in devices, masks, and digital health platforms, with future growth anticipated from GLP-1 usage and wearable technology adoption.
Resmed CFO Sandercock sells $224k in stock
Resmed's CFO, Brett Sandercock, sold 1,000 shares of company stock worth $224,310 under a pre-arranged trading plan, yet the company maintains a "GREAT" financial health score and has consistently raised its dividend. This transaction comes amidst positive financial results for ResMed, including beating EPS forecasts and meeting revenue expectations, leading to several analysts raising their price targets while others maintain a cautious "Hold" rating.
ResMed (RMD) CFO Sandercock sells 1,000 shares in open market trade
ResMed's CFO, Brett Sandercock, sold 1,000 shares of the company's common stock in an open-market transaction for $224.31 per share. This sale was pre-arranged under a Rule 10b5-1 plan adopted in February 2025. Following the transaction, Sandercock directly holds 83,495 shares of ResMed Common Stock.
J. Safra Sarasin Holding AG Sells 10,794 Shares of ResMed Inc. $RMD
J. Safra Sarasin Holding AG significantly reduced its stake in ResMed Inc. ($RMD) by selling 10,794 shares, lowering its total holdings to 1,565 shares valued at $377,000. Other institutional investors like SJS Investment Consulting Inc. and ORG Partners LLC increased their positions, while ResMed's CEO and a Director also sold shares. The company recently reported strong earnings, declared a quarterly dividend, and has a "Moderate Buy" consensus rating from analysts with an average price target of $299.27.
Spire Wealth Management Cuts Stock Holdings in ResMed Inc. $RMD
Spire Wealth Management significantly reduced its stake in ResMed Inc. ($RMD) by 80.5% in the fourth quarter, selling 5,666 shares and retaining 1,373 shares valued at around $331,000. This comes as company insiders also offloaded shares, with Director Peter C. Farrell and CEO Michael J. Farrell selling a combined 6,991 shares. Despite insider sales, ResMed beat quarterly earnings expectations and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $299.27.
Resmed director Farrell sells $450,000 in stock
Peter C. Farrell, a director at ResMed Inc. (NYSE:RMD), sold 2,000 shares of company stock for $450,000 on April 1, 2026, under a Rule 10b5-1 trading plan. The medical device company, which has "GREAT" financial health and has raised its dividend for 14 consecutive years, appears undervalued according to InvestingPro analysis, despite varied recent analyst outlooks. ResMed also reported strong Q2 fiscal 2026 earnings, surpassing EPS expectations.
Resmed director Farrell sells $450,000 in stock By Investing.com
Peter C. Farrell, a director at ResMed Inc (NYSE:RMD), sold 2,000 shares of the company's common stock for $450,000 on April 1, 2026. This transaction was part of a Rule 10b5-1 trading plan. Despite the sale, ResMed maintains a "GREAT" financial health score, has raised its dividend for 14 consecutive years, and is considered undervalued by InvestingPro.
Resmed director Farrell sells $450,000 in stock
Peter C. Farrell, a director at ResMed Inc. (NYSE:RMD), sold 2,000 shares of company stock for $450,000, as documented in an SEC filing on April 1, 2026. The sale was executed under a Rule 10b5-1 trading plan and occurred while ResMed is considered undervalued by InvestingPro, despite its "GREAT" financial health and 14 consecutive years of dividend increases.
ResMed (NYSE: RMD) director sells 2,000 shares under Rule 10b5-1 plan
ResMed Inc. director Peter C. Farrell sold 2,000 shares of ResMed Common Stock at $225.00 per share, totaling $450,000, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Farrell directly holds 60,773 shares. This sale was reported via a Form 4 SEC filing, indicating a moderate filing impact and negative sentiment.
Resmed Insider Sold Shares Worth $450,000, According to a Recent SEC Filing
An insider at Resmed sold shares valued at $450,000, as detailed in a recent SEC filing. This transaction was reported on April 2, 2026, by MT Newswires. Resmed specializes in medical devices, masks, and software for respiratory disorders.
ResMed Inc. (RMD) stock price, news, quote and history
This article provides comprehensive financial data, news, and historical information for ResMed Inc. (RMD). It includes real-time stock quotes, key statistics, performance over various periods, an overview of the company's operations in medical devices and cloud-based software, and analyst insights. The report also lists financial highlights, profitability metrics, and allows for comparison with similar companies in the Medical Instruments & Supplies industry.
Peter C. Farrell (RMD) sells 6,000 shares via Rule 144 notices (NYSE: RMD)
Peter C. Farrell has filed a Rule 144 notice, disclosing the sale of 6,000 shares of ResMed Inc. (RMD) common stock through three separate transactions of 2,000 shares each on January 7, 2026, February 4, 2026, and March 4, 2026. The filing also indicates option-derived share entries from November 2014 and November 2015. This Form 144 report details routine procedural sales of restricted securities.
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
Resmed (NYSE: RMD, ASX: RMD) announced it will release its third-quarter fiscal year 2026 financial and operational results on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, management will host a webcast to discuss the results, which will be accessible via their investor relations website. A replay of the webcast and a phone replay will also be available after the live event.
Resmed to post quarterly results after market close on April 30
ResMed (NYSE: RMD) announced it will release its third-quarter fiscal year 2026 financial and operational results on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via its investor relations website, with replays also available. The announcement emphasizes the company's consistent practice of providing transparency regarding its financial disclosures.
Affiliate proposes three 1,000-share sales for RMD (NYSE: RMD) — broker listed
An affiliate of ResMed (NYSE: RMD) has filed a Form 144, indicating proposed sales of 3,000 common shares across three separate transactions. Each sale involves 1,000 shares with reported values ranging from $241,750 to $257,030, and Fidelity Brokerage Services LLC is listed as the broker. The filing also notes a prior restricted stock vesting of 1,000 shares on November 11, 2023.
ResMed Inc. stock rises Tuesday, still underperforms market
ResMed Inc. (RMD) stock increased by 2.02% to $224.48 on Tuesday, breaking a four-day losing streak. Despite this gain, the stock still underperformed the broader market, as the S&P 500 Index rose 2.91% and the Dow Jones Industrial Average rose 2.49% on the same day.
BSX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP has reminded Boston Scientific (BSX) investors of the May 4, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Boston Scientific made misleading statements regarding its U.S. EP segment's growth rate, causing investor losses when the company reported disappointing Q4 2025 results and issued weak guidance for fiscal year 2026. Investors who purchased Boston Scientific securities between July 23, 2025, and February 3, 2026, and suffered losses are encouraged to contact the firm.
Global Sleep Apnea Diagnostic Systems Market Expands with North America Leadership and Innovations from Philips, ResMed, Natus Medical Driving Home-Based Diagnostics
The global Sleep Apnea Diagnostic Systems Market is projected to grow from USD 4.483 billion in 2025 to USD 6.1 billion by 2035, driven by the increasing prevalence of sleep disorders, rising awareness, and technological advancements. North America leads the market, with key players like Philips, ResMed, and Natus Medical driving innovations in home-based diagnostics, wearable devices, and AI-enabled analytics. Actigraphy monitoring devices currently hold the largest market share due to their affordability and ease of use in ambulatory settings.
ResMed Earnings Preview: What to Expect
ResMed Inc. (RMD) is set to release its Q3 2026 earnings, with analysts expecting diluted EPS of $2.77, a 16.9% increase year-over-year. Despite the company consistently beating Wall Street's EPS estimates in the past four quarters, its stock has marginally declined over the last 52 weeks, underperforming the S&P 500. Analysts currently hold a "Moderate Buy" rating for RMD, projecting a significant upside from current levels.
ResMed Inc. Stock: Navigating Sleep Apnea Market Leadership Amid Demographic Tailwinds and Digital Innovation
ResMed Inc. leads the sleep apnea and respiratory care market, benefiting from an aging global population and rising diagnoses. The company excels in digital health solutions, leveraging software-as-a-service (SaaS) platforms like Brightree and myAir to improve patient adherence and provide recurring revenue. Despite competitive pressures and regulatory risks, ResMed's strong market position, extensive patent portfolio, and strategic shift towards digital innovation position it for continued growth, especially in the North American market.
ResMed Inc. (RMD) Launches Global Sleep Institute at World Sleep Congress
ResMed Inc. (RMD) announced the launch of its Global Sleep Institute at the World Sleep Congress in Rio de Janeiro, Brazil. The institute aims to advance sleep science and improve awareness, screening, and treatment for sleep-disordered breathing and sleep health. This initiative underscores ResMed's commitment to global health and research in sleep medicine.
ICU Medical (FRA:IC7) Issuance of Debt : €0 Mil (TTM As of Dec. 2025)
ICU Medical (FRA:IC7) reported an issuance of debt of €0 million for the trailing twelve months (TTM) ended December 2025 and for the quarter ended December 2025. GuruFocus rates ICU Medical with a GF Score of 84/100 and considers the stock "Fairly Valued" with a GF Value of €110.46 against a current price of €107.00, noting 4 warning signs. The company is a key player in infusion therapy systems and supplies, generating over 60% of its sales domestically in the US.
Microbot Medical (HAM:CY9D) Land And Improvements : €0.00 Mil (As of Dec. 2025)
This article reports that Microbot Medical (HAM:CY9D) has €0.00 million in Land And Improvements as of December 2025. GuruFocus rates the company with a GF Score of 43/100 and notes 2 warning signs for investors. The article provides historical data and a definition of "Land And Improvements" for context.
UTAH MEDICAL PRODUCTS Cyclically Adjusted Book per Share: $3
This article from GuruFocus focuses on Utah Medical Products (UTMD) and its Cyclically Adjusted Book per Share, which was $32.42 as of September 2025. It explains the calculation of this metric, which averages the inflation-adjusted book value per share over the past 10 years, similar to Professor Robert Shiller's E10 concept. The article notes that UTMD has a GF Score of 81/100 and is considered "Fairly Valued" with 4 warning signs.
Vanguard (RMD) disaggregates holdings; reports zero ownership in ResMed
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership in ResMed Inc (RMD). This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, in accordance with SEC guidance. Investors should expect future separate filings from Vanguard affiliates detailing their individual holdings in ResMed.
Regatta Capital Group LLC Invests $2.51 Million in ResMed Inc.
Regatta Capital Group LLC has invested $2.51 million in ResMed Inc., acquiring 10,412 shares of the medical equipment provider's stock. This investment, made during the fourth quarter of 2025, signals institutional confidence in ResMed's growth prospects and leadership in the sleep-disordered breathing and respiratory conditions market. ResMed is a global medical device company focusing on these chronic conditions.
Regatta Capital Group LLC Takes $2.51 Million Position in ResMed Inc. $RMD
Regatta Capital Group LLC has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing 10,412 shares valued at approximately $2.51 million. Institutional investors now collectively own nearly 55% of the company, with significant stakes held by Norges Bank, Vanguard, and others. Analysts currently hold a "Moderate Buy" rating for ResMed, with an average price target of $299.27, while the company continues to pay a quarterly dividend of $0.60.
Dakota Wealth Management Has $8.18 Million Holdings in ResMed Inc. $RMD
Dakota Wealth Management significantly increased its stake in ResMed Inc. ($RMD) by 29.1% in Q4, now holding 33,948 shares valued at approximately $8.18 million. ResMed exceeded Q4 earnings estimates with an EPS of $2.81 and revenue of $1.42 billion, marking an 11% year-over-year increase. Despite recent insider selling, institutional investors maintain a substantial 54.98% ownership, and analysts rate the stock with a "Moderate Buy" and an average target price of $299.27.
Assenagon Asset Management S.A. Has $19.43 Million Stock Holdings in ResMed Inc. $RMD
Assenagon Asset Management S.A. increased its stake in ResMed Inc. (NYSE:RMD) by 136.8% in the fourth quarter, bringing its total holdings to $19.43 million, representing 0.06% of the company. Other institutional investors also adjusted their positions in ResMed. The medical equipment provider has received a "Moderate Buy" consensus rating from analysts, with an average target price of $299.27, and recently reported strong quarterly earnings and a dividend announcement.
Disc Medicine expands rare disease trial to 183 patients; data due in Q4
Disc Medicine (NASDAQ:IRON) announced the completion of enrollment for its Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP). The study was expanded to 183 participants from an original target of 150 due to high demand and completed enrollment in under a year. Topline data are expected in Q4 2026, with an FDA decision anticipated by mid-2027.
ResMed Inc. stock outperforms market despite losses on the day
ResMed Inc. (RMD) shares dropped 1.68% to $222.50, marking its second consecutive day of losses. Despite this, the stock managed to outperform the broader market, as the S&P 500 Index and Dow Jones Industrial Average experienced larger declines of 1.74% and 1.01% respectively.
ResMed Inc. stock: Leader in sleep and respiratory care with strong North American market presence
ResMed Inc. is a leading company in sleep and respiratory care, specializing in devices for sleep apnea and respiratory disorders, primarily targeting the North American market. The company benefits from strong demand driven by aging populations and increasing health awareness, with its core business focused on CPAP devices, bilevel devices, and cloud-based software. ResMed maintains a robust financial position and offers investors exposure to a resilient healthcare segment, emphasizing innovation, data-driven outcomes, and recurring revenue streams.
Time To Buy The Dip In Verisk Analytics Stock?
Verisk Analytics (VRSK) stock has recently fallen by 13.9% in less than a month, prompting the question of whether this dip represents a buying opportunity. Historically, VRSK stock has shown a median return of 34% within 12 months after sharp dips, and it passes basic financial quality checks. The article suggests that dip buying can be a viable strategy for quality stocks like VRSK, which has proven to recover from previous downturns.
Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks
This article analyzes Q4 earnings for ResMed (RMD) and other patient monitoring stocks, highlighting their performance, challenges, and future growth prospects. While the sector benefits from an aging population and digital health adoption, companies face high R&D costs and regulatory hurdles. ResMed, iRhythm, DexCom, and Insulet all reported strong Q4 revenues, though market reactions to their earnings varied, with most stocks experiencing a decline post-results.
ResMed Inc. (RMD.AX) Alternative Data Analytics - Social & Digital Signals
This article provides an analysis of ResMed Inc.'s (RMD.AX) social and digital presence across various platforms, including Facebook, Twitter, YouTube, LinkedIn, Instagram, Glassdoor, and TikTok. It details key metrics such as follower counts, engagement rates, and review ratings for each platform. The piece explains how investors can use these alternative data signals to gain insights into brand visibility, marketing effectiveness, customer sentiment, talent acquisition, and overall company health, supplementing traditional financial analysis.
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector
Haemonetics Corp stock is currently in a holding pattern due to a lack of fresh catalysts in the blood management sector, despite steady demand for its plasma collection and transfusion technologies. The company, a leader in automated blood processing, benefits from recurring disposable sales in its Plasma and Blood Center segments. Investors should consider the company's solid financial health and
ResMed Inc stock faces pressure amid slowing sleep apnea device demand and insurance reimbursement h
ResMed Inc's stock is under pressure due to a significant slowdown in demand for its CPAP machines in the US, primarily caused by increasing competition from GLP-1 weight-loss drugs. These drugs are reducing obesity-related sleep apnea cases, impacting ResMed's sales and leading to a sharp decline in its stock price on the NYSE. The company is exploring innovation and international market expansion to mitigate these challenges, but investors are concerned about reimbursement risks and the changing sleep health landscape.
